Certificate of Compliance issued by the European regulator, SUKL, Czech Republic for Glenmark’s Baddi manufacturing facility

16 Dec 2019 | Read More

Glenmark receives ANDA approval for Metformin Hydrochloride Extended-Release Tablets USP, 500 mg and 1000 mg

26 Nov 2019 | Read More

Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20

14 Nov 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Adapalene and Benzoyl Peroxide Gel, 0.1%|2.5%

11 Nov 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Abiraterone Acetate Tablets USP, 250 mg

17 Oct 2019 | Read More

Glenmark Pharmaceuticals receives tentative ANDA approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg

9 Oct 2019 | Read More

Glenmark receives approval from Russian Ministry of Healthcare to market Montlezir (Levocetirizine+Montelukast) film-coated tablets

30 Sep 2019 | Read More

Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the second year in a row

26 Sep 2019 | Read More

Glenmark Receives Orphan Drug Designation for GBR 1342, a Bispecific Antibody Candidate Under Evaluation for the Treatment of Multiple Myeloma

17 Sep 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Foam, 0.05%

10 Sep 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Pimecrolimus Cream, 1%

30 Aug 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

23 Aug 2019 | Read More

Glenmark receives approval for combination of Remogliflozin Etabonate and Metformin Hydrochloride for adults with type 2 diabetes in India

19 Aug 2019 | Read More

Glenmark’s consolidated revenue at Rs. 23,228.79 Mn. for Q1 FY 2019 – 20

13 Aug 2019 | Read More

Glenmark & Torrent sign licensing agreement for co-marketing of Remogliflozin Etabonate in India

11 Jul 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Ranolazine Extended-Release Tablets, 500 mg and 1,000 mg

9 Jul 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Ezetimibe and Simvastatin Tablets, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg

28 Jun 2019 | Read More

 Glenmark to partner with Novartis to promote, commercialize and distribute three respiratory products in Brazil

24 Jun 2019 | Read More

Glenmark Pharmaceuticals receives tentative ANDA approval for Clindamycin Phosphate Foam, 1%

20 Jun 2019 | Read More

Glenmark’s consolidated revenue rises 12.44% to Rs. 25,634.74 Mn. for Q4 FY 2018-19

29 May 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg

27 May 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Solifenacin Succinate Tablets, 5 mg and 10 mg

21 May 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg and 40 mg

14 May 2019 | Read More

 Glenmark Pharmaceuticals Announces Results from a Phase 3 Study of Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, in Patients Aged 6 to Under 12 Years  

9 May 2019 | Read More

Glenmark appoints Dr. Yasir Rawjee as Chief Executive Officer of Glenmark Life Sciences, its subsidiary for the API business

7 May 2019 | Read More

Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication

3 May 2019 | Read More

Glenmark launches novel, globally-researched anti-diabetes drug Remogliflozin in India

30 Apr 2019 | Read More

Glenmark receives approval from Russian Ministry of Healthcare to market Momate Rhino metered nasal spray as an Over-the-Counter (OTC) product

25 Apr 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clindamycin and Benzoyl Peroxide Gel, 1%|5%

15 Mar 2019 | Read More

Glenmark Announces Appointment of Alessandro Riva as CEO of its New Innovation Company

6 Mar 2019 | Read More

Glenmark receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets USP

5 Mar 2019 | Read More

Glenmark Pharmaceuticals Announces Presentation of New Subtype Analysis of GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the American Academy of Dermatology Annual Meeting

4 Mar 2019 | Read More

Glenmark Pharmaceuticals Announces Results from New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at AAAAI 2019 Annual Meeting

26 Feb 2019 | Read More

Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting

20 Feb 2019 | Read More

Glenmark receives ANDA approval for Clobetasol Propionate Foam, 0.05%

18 Feb 2019 | Read More

Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19

14 Feb 2019 | Read More

Glenmark to spin off its innovation business into a new company in the US

14 Feb 2019 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg

11 Feb 2019 | Read More

Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

7 Feb 2019 | Read More

Glenmark Pharmaceuticals enters into an Exclusive License Agreement with Grandpharma (China) Co. Ltd. for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in China

6 Feb 2019 | Read More

Glenmark receives tentative ANDA approval for Topiramate Extended-Release Capsules

24 Jan 2019 | Read More

Glenmark receives tentative ANDA approval for Abiraterone Acetate Tablets USP, 250 mg

23 Jan 2019 | Read More

Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in South Korea

10 Jan 2019 | Read More